OnabotulinumtoxinA (Botox)
Treatment for Migraine
Typical Dosage: 155 units injected across 31 sites
Effectiveness
72%
Safety Score
65%
Clinical Trials
63
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
155 units injected across 31 sites
Time to Effect
2-4 weeks
Treatment Duration
Long-term (every 12 weeks)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$600
Side Effect Mgmt:$200
Total Annual:$4,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$100,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$10,000
Cost per Remission
$40,000
Active Clinical Trials
3 active trials recruiting for OnabotulinumtoxinA (Botox) in Migraine
BOTOX® vs. XEOMIN® for Chronic Migraine
NCT05598723RECRUITINGPHASE3
128 participants
INTERVENTIONAL
Jacksonville, United States
Started: Feb 24, 2023
Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine
NCT07780136NOT YET RECRUITINGPHASE4
70 participants
INTERVENTIONAL
Started: Oct 1, 2026
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
NCT07535723NOT YET RECRUITINGNA
90 participants
INTERVENTIONAL
Al Fayyum, Egypt
Started: Apr 1, 2026
Completed Clinical Trials
10 completed trials for OnabotulinumtoxinA (Botox) in Migraine
Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population
NCT03055767COMPLETEDPHASE2
17 participants
INTERVENTIONAL
Irvine, United States +1 more
Started: Mar 1, 2017
Calcitonin Gene-related Peptide Levels in Chronic Migraine
NCT01071096COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Springfield, United States +1 more
Started: Jun 1, 2010
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
NCT01833130COMPLETEDPHASE4
52 participants
INTERVENTIONAL
San Francisco, United States
Started: Apr 1, 2013
Efficacy of OnabotulinumtoxinA in Migraine
NCT04578782COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Pavia, Italy
Started: Mar 13, 2018
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
NCT01516892COMPLETEDPHASE4
716 participants
INTERVENTIONAL
Scottsdale, United States +31 more
Started: Dec 1, 2011
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
NCT02037425COMPLETEDPHASE4
44 participants
INTERVENTIONAL
Springfield, United States
Started: Apr 1, 2014
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
NCT01700387COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Springfield, United States
Started: Oct 1, 2012
Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.
NCT03698409COMPLETEDPHASE4
68 participants
INTERVENTIONAL
Syracuse, United States
Started: Jan 1, 2019
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
NCT02502123COMPLETED
215 participants
OBSERVATIONAL
Calgary, Canada +14 more
Started: Jul 2, 2015
(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
NCT03381261COMPLETEDPHASE4
37 participants
INTERVENTIONAL
Boston, United States
Started: Dec 1, 2017
Showing 20 of 66 total trials